Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• Low ctDNA tumor fraction indicates potential for long-term clinical benefit during treatment with immune checkpoint inhibitors.
• Patients with tumor fraction values below limit of quantification (LOQ) at both timepoints exhibited better outcomes.
• The study employed a real-world cohort, providing insights into the effectiveness of immune therapies across diverse cancer types.
• This analysis emphasizes the importance of tumor fraction monitoring in clinical settings, guiding personalized treatment options.

Abstract